Carbon Nanomaterials As Carriers for the Anti-cancer Drug Doxorubicin: a Review on Theoretical and Experimental Studies

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2024 Aug 8

PMID 39114152

Authors

K Gayathri

R Vidya

Affiliations

Soon will be listed here.

Abstract

The incidence of cancer is increasing worldwide in a life-threatening manner. In such a scenario, the development of anti-cancer drugs with minimal side effects and effective drug delivery systems is of paramount importance. Doxorubicin (DOX) is one of the powerful anti-cancer drugs from the chemical family anthracycline, which is used to treat a wide variety of cancers, including breast, prostate, ovarian, and hematological malignancies. However, DOX has been associated with many side effects, including lethal cardiotoxicity, baldness, gastrointestinal disturbances and cognitive function impairment. Even though DOX is administered in liposomal formulations to reduce its toxicity and enhance its therapeutic profile, the liposomal formulations themselves have certain therapeutic profile limitations such as "palmar-plantar erythrodysesthesia (PPE)", which shows severe swelling and redness in the skin, thus restricting the dosage and reducing patient compliance. In contemporary chemotherapy research, there is a great interest in the utilization of nanomaterials for precise and targeted drug delivery applications, especially using carbon-based nanomaterials. This review provides a comprehensive overview of both experimental and theoretical scientific works, exploring diverse forms of carbon-based materials such as graphene, graphene oxide, and carbon nanotubes that function as carriers for DOX. In addition, the review consolidates information on the fate of the carriers after the delivery of the payload at the site of action through different imaging techniques and the various pathways through which the body eliminates these nanomaterials. In conclusion, the review presents a detailed overview of the toxicities associated with these carriers within the human body, contributing to the development of enhanced drug delivery systems.

References

Novoselov K, Geim A, Morozov S, Jiang D, Zhang Y, Dubonos S . Electric field effect in atomically thin carbon films. Science. 2004; 306(5696):666-9. DOI: 10.1126/science.1102896. View

Wu W, Li T . Unraveling the in vivo fate and cellular pharmacokinetics of drug nanocarriers. Adv Drug Deliv Rev. 2019; 143:1-2. DOI: 10.1016/j.addr.2019.08.003. View

Shen J, Li J, Dai J, Zhou M, Ren H, Zhang L . Molecular dynamics study on the adsorption and release of doxorubicin by chitosan-decorated graphene. Carbohydr Polym. 2020; 248:116809. DOI: 10.1016/j.carbpol.2020.116809. View

Khoshoei A, Ghasemy E, Poustchi F, Shahbazi M, Maleki R . Engineering the pH-Sensitivity of the Graphene and Carbon Nanotube Based Nanomedicines in Smart Cancer Therapy by Grafting Trimetyl Chitosan. Pharm Res. 2020; 37(8):160. PMC: 7399690. DOI: 10.1007/s11095-020-02881-1. View

Barenholz Y . Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2):117-34. DOI: 10.1016/j.jconrel.2012.03.020. View

Wang Z, Zhou C, Xia J, Via B, Xia Y, Zhang F . Fabrication and characterization of a triple functionalization of graphene oxide with Fe3O4, folic acid and doxorubicin as dual-targeted drug nanocarrier. Colloids Surf B Biointerfaces. 2013; 106:60-5. DOI: 10.1016/j.colsurfb.2013.01.032. View

Yan Y, Wang R, Hu Y, Sun R, Song T, Shi X . Stacking of doxorubicin on folic acid-targeted multiwalled carbon nanotubes for in vivo chemotherapy of tumors. Drug Deliv. 2018; 25(1):1607-1616. PMC: 6201812. DOI: 10.1080/10717544.2018.1501120. View

Alves A, Magarkar A, Horta M, Lima J, Bunker A, Nunes C . Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies. Sci Rep. 2017; 7(1):6343. PMC: 5524714. DOI: 10.1038/s41598-017-06445-z. View

Dumortier H . When carbon nanotubes encounter the immune system: desirable and undesirable effects. Adv Drug Deliv Rev. 2013; 65(15):2120-6. DOI: 10.1016/j.addr.2013.09.005. View

10.

Moustaoui H, Movia D, Dupont N, Bouchemal N, Casale S, Djaker N . Tunable Design of Gold(III)-Doxorubicin Complex-PEGylated Nanocarrier. The Golden Doxorubicin for Oncological Applications. ACS Appl Mater Interfaces. 2016; 8(31):19946-57. DOI: 10.1021/acsami.6b07250. View

11.

Sohrabi S, Khedri M, Maleki R, Moraveji M . Molecular engineering of the last-generation CNTs in smart cancer therapy by grafting PEG-PLGA-riboflavin. RSC Adv. 2022; 10(67):40637-40648. PMC: 9057702. DOI: 10.1039/d0ra07500k. View

12.

Carvalho C, Santos R, Cardoso S, Correia S, Oliveira P, Santos M . Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009; 16(25):3267-85. DOI: 10.2174/092986709788803312. View

13.

Cao L, Zhu Y, Wang W, Wang G, Zhang S, Cheng H . Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy. Front Bioeng Biotechnol. 2021; 9:798882. PMC: 8688801. DOI: 10.3389/fbioe.2021.798882. View

14.

Su Z, Dong S, Zhao S, Liu K, Tan Y, Jiang X . Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat. 2021; 58:100777. DOI: 10.1016/j.drup.2021.100777. View

15.

Kotchey G, Zhao Y, Kagan V, Star A . Peroxidase-mediated biodegradation of carbon nanotubes in vitro and in vivo. Adv Drug Deliv Rev. 2013; 65(15):1921-32. PMC: 3855904. DOI: 10.1016/j.addr.2013.07.007. View

16.

Garriga R, Herrero-Continente T, Palos M, Cebolla V, Osada J, Munoz E . Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines. Nanomaterials (Basel). 2020; 10(8). PMC: 7466705. DOI: 10.3390/nano10081617. View

17.

Ashrafizadeh M, Saebfar H, Gholami M, Hushmandi K, Zabolian A, Bikarannejad P . Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opin Drug Deliv. 2022; 19(4):355-382. DOI: 10.1080/17425247.2022.2041598. View

18.

Palmerston Mendes L, Pan J, Torchilin V . Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules. 2017; 22(9). PMC: 5600151. DOI: 10.3390/molecules22091401. View

19.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

20.

Thakur C, Neupane R, Karthikeyan C, Ashby Jr C, Jayachandra Babu R, Boddu S . Lysinated Multiwalled Carbon Nanotubes with Carbohydrate Ligands as an Effective Nanocarrier for Targeted Doxorubicin Delivery to Breast Cancer Cells. Molecules. 2022; 27(21). PMC: 9657689. DOI: 10.3390/molecules27217461. View